Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer

Ayse Ceren Mutgan 1, H. Erdinc Besikcioglu 1,2, Shenghan Wang 1, Helmut Friess 1, Güralp O. Ceyhan 1 and Ihsan Ekin Demir 1*

Abstract
Pancreatic ductal adenocarcinoma (PDAC) is unrivalled the deadliest gastrointestinal cancer in the western world. There is substantial evidence implying that insulin and insulin-like growth factor (IGF) signaling axis prompt PDAC into an advanced stage by enhancing tumor growth, metastasis and by driving therapy resistance. Numerous efforts have been made to block Insulin/IGF signaling pathway in cancer therapy. However, therapies that target the IGF1 receptor (IGF-1R) and IGF subtypes (IGF-1 and IGF-2) have been repeatedly unsuccessful. This failure may not only be due to the complexity and homology that is shared by Insulin and IGF receptors, but also due to the complex stroma-cancer interactions in the pancreas. Shedding light on the interactions between the endocrine/exocrine pancreas and the stroma in PDAC is likely to steer us toward the development of novel treatments. In this review, we highlight the stroma-derived IGF signaling and IGF-binding proteins as potential novel therapeutic targets in PDAC.

Keywords: IGF-1, Insulin, Pancreatic cancer, Stroma

Background
The latest demographic studies on pancreatic ductal adenocarcinoma (PDAC) indicate that, unless novel diagnostic tools and treatments are developed, PDAC is expected to be the 2nd leading cancer-related cause of death in the United States before 2030 [1].

Smoking, alcohol usage, family history of chronic pancreatitis, male gender, advanced age, high body mass index (BMI) and diabetes mellitus (DM) are risk factors for developing PDAC [2, 3]. Among these, type 2 DM/T2DM has been postulated to be a reason for screening for PDAC, as it frequently precedes the diagnosis of PDAC [4]. Thus, researchers have long wondered whether T2DM is a contributor or a consequence of the PDAC.

Most T2DM patients have hyperinsulinemia, a condition that defines high insulin levels in the blood. Insulin regulates glucose, lipid and amino acid homeostasis, acts on organs such as liver, muscle and adipose tissue lifelong. In a state of hyperinsulinemia, insulin increases bio-availability of another class of factors, i.e. insulin-like growth factors (IGF), which are one of the key regulators of energy metabolism and growth [5].

Due to the plethora of metabolic derangements caused by hyperinsulinemia, researchers have long considered a potentially decisive role for Insulin/IGF signaling in neoplasia, including PDAC [6]. Although the first results of the clinical trials with compounds that target insulin/IGF signaling in PDAC have been disappointing, researchers have recently directed their research towards understanding the role of Insulin/IGF-1R signaling in the cross-talk between cancer cells and stroma. Indeed, there is still a major knowledge gap in how exactly the dynamic stroma of PDAC can affect the complex endocrine and exocrine compartments of the pancreas. Thus, enlightening the insulin/IGF-driven interaction between cancer cells, endocrine pancreas, and the stroma may be key to understanding the progression of PDAC and of PDAC-associated diabetes, and thereby open the door to the development of efficient therapies that target cancer cells and tumor stroma at the same time. In this review,
we summarize the role of Insulin/IGF signaling pathway in the reciprocal interactions of stromal cells with cancer cells in the PDAC microenvironment and suggest a research line to that may create opportunities to develop novel treatments for PDAC.

Tumor cell-intrinsic effects of IGF signaling in PDAC

Insulin and IGF are closely related and conserved systemic growth factors that are produced by different organs. Insulin is produced by β-cells of the pancreas, and IGF ligands IGF-1 and IGF-2 are produced by the liver in response to growth hormone (GH) stimulation that is secreted from the anterior pituitary gland [6]. Insulin (IR) and IGF (IGF)-receptors belong to the receptor tyrosine kinase (RTK) family. There are two different insulin receptors and two different IGF receptors, IR-A/IR-B and IGF-1R/IGF-2R, respectively. IGF-1R is expressed nearly in all tissues [7, 8]. Moreover, 40–90% of the IGF-1R on tissues are found to be IGF-1R/IR hybrid receptors [7, 8]. Such hybrid receptors display higher binding affinity to IGF ligands compared to insulin [9]. IGF-2R is ubiquitously expressed, and yet IGF-2R receptor activation does not induce activation of insulin/IGF signaling axis [6]. IGF-2R can only bind to IGF-2, but insulin, IGF-1 and IGF-2 can bind to IR, IGF-1R and IR/IGF-1R hybrid receptors with varying binding affinity (Fig. 1) [10–12]. Thus, the crosstalk between insulin and IGF signaling axis designates the complexity of this signaling pathway and its numerous modes of activation.

IGF-1 and IGF-1R are known to be abundantly expressed in the PDAC tissue, and activated Insulin/IGF signaling in PDAC cells was found to regulate the basal growth rate of the cancer cells [13, 14]. In fact, IGF-1R expression is correlated with higher tumor grade, and its co-expression with epidermal growth factor receptor (EGFR) was shown to be be significantly associated with poor survival in PDAC [15]. IGF-2R mRNA and protein levels were previously shown to be upregulated in human pancreatic cancer tissues, particularly in the nucleus of ductal-like pancreatic cancer cells, when compared to the normal pancreatic tissue [16]. When the inability of IGF-2R to induce Insulin/IGF signaling is considered, IGF-2R seems to decrease the bioavailability of IGF-2 in the circulation and attenuates insulin/IGF signaling axis by clearance of the circulating IGF-2.

IGF signaling pathway further consists of six IGF binding proteins (IGFBPs) and 10 IGFBP-related proteins (IGFBP-rPs) [17]. In circulation, IGFBPs are found in a protein-bound form with IGFBPs [18], protecting the ligands from degradation, and extending the half-life and stability of the circulating IGFs [17, 19]. Free IGFBPs have a higher binding affinity to IGFBPs than to IGF-1R, IR and IR/IGF-1R hybrid receptors. Therefore, distribution of IGFBPs in tissues and attenuation of the Insulin/IGF signaling is regulated by IGFBPs, which regulate the bioavailability of IGFBPs and contribute to attenuation of the Insulin/IGF signaling axis [17, 19, 20]. In the serum and in the pancreas of PDAC patients, IGFBP-1, IGFBP-3, IGF-1 and IGF1R are over-expressed [21]. In addition, high IGF-1 levels in the serum of PDAC patients are associated with high levels of IGFBP-3 again in the serum when compared to healthy individuals [22]. Besides, increase in the serum levels of IGFBP-3 seems to be associated with the risk of death from PDAC [22]. Recent studies highlighted that high IGF-1/low IGFBP-3 concentrations might be associated with increased PDAC risk [23, 24]. Accordingly, patients with high IGF-1R/low IGFBP-3 expression in the pancreas are diagnosed with advanced PDAC and exhibit overall poor survival [25]. This observation suggests that IGF-1/IGFBP-3 expression levels might be altered during the progression of PDAC, but, most importantly, elevated levels of free IGF-1 together with IGF-1R expression is correlated with poor prognosis and survival. In addition, IGFBP-3 is one of the p53 response genes and is involved in p53-induced apoptosis independent of IGF-1 signaling [26]. Interestingly, p53 can also directly modulate IGF-1R expression by regulating the IGF-1R gene promoter [27]. Therefore, inactivation or altered expression of tumor suppressors such as p53 might be another reason for the overexpression of IGF-1R receptors in PDAC.

IGF signaling in the PDAC stroma

Despite the presence of several studies that demonstrated the effects of activated IGF signaling on cancer cells in PDAC, the impact of stromal IGF signaling or stroma-derived IGFBPs in PDAC has been recognized only very recently. PDAC cells are typically surrounded by a dense stroma, which is classically assumed to serve as a protective barrier against tumor spread [28, 29]. The majority of tumor stroma in PDAC is composed of “acellular” components. i.e. extracellular matrix proteins such as collagen, fibronectin or laminin. The “cellular” stroma contains the key actors of the tumor microenvironment such as immune cells, endothelial cells, pancreatic stellate cells, fibroblasts, or neural cells. There are five lines of evidence that suggests a key role for stromal IGF signaling in the progression of PDAC (Figs. 2, 3).

Activated stromal (myo-) fibroblasts as a leading source of IGF-1 in PDAC

In more than 90% of PDAC cases, KRAS is over-activated by mutations [30]. KRAS(12G)-mutated cancer cells activate stromal fibroblasts via Sonic Hedgehog (Shh) pathway [31]. This activation does not only provide survival signals for the fibroblasts, but also activates IGF-1R on cancer cells via IGF-1 that is secreted by fibroblasts and by pancreatic stellate cells (PaSCs) in
response to Shh (Fig. 2) [31–33]. Indeed, current evidence suggests that stromal cells may be the foremost source of IGF-1 in the PDAC microenvironment. IGFs that are secreted from stromal cells can act on cancer cells via direct IGF-1R signaling, and together with hepatocyte growth factor/HGF, can phosphorylate Annexin A2/AnxA2, a protein that has a well-established role in invasion/metastasis [33].

In addition to Shh, stromal (myo-) fibroblasts can also become activated under tumor hypoxia. Indeed, PDACs are hypovascularized and thus hypoxic tumors [34]. In PDAC, cancer-associated fibroblasts produce IGF-1 under hypoxic conditions and promote tumor cell migration via IGF-1R signaling under hypoxia in vitro [34]. Remarkably, the migration capacity of tumor-derived PaSCs is also prominently greater both at basal conditions and after IGF-1 stimulation [35]. One molecular reason for this may be the expression levels of IGFBP in PaSCs: Tumor PaSCs have lower expression levels of IGFBP-3 and higher expression levels of IGFBP-2 compared to the normal PaSCs. Considering the greater migratory capacity of tumor PaSCs when compared to normal PaSCs, the reduction in IGFBP-3 levels seems to outweigh the elevation of IGFBP-2, resulting in a net increase in the IGF-1 availability [35].
Control of IGFBP levels by stromal proteases

Expression levels of the regulatory IGFBPs in the liver and concentration of these proteins in circulation or in the tumor tissue are subject to modulation via proteases [36]. Importantly, the desmoplastic pancreatic cancer stroma contains many different proteases. Such proteases may cause degradation of IGFBPs and lead to increased amounts of free IGFs within the tissue. For instance, nerve growth factor (NGF), a family member of kallikrein proteases, can degrade IGFBP-3, IGFBP-4 and IGFBP-6 and is strongly up-regulated in PDAC [37, 38]. Similarly, cathepsin D, which also displays high expression levels in PDAC patients compared to healthy individuals, can mediate proteolysis of IGFBPs [39, 40]. Likewise, IGFBP-1, −2, −3, −4 and - 6, are substrates of MMP-2, MMP-7 and MMP-9 proteases, which are expressed in the peritumoral stroma and cancer cells in PDAC [41–44]. Direct modulation of IGFBPs at protein level via stromal proteases can be considered as one of the sources of activated IGF signaling in PDAC.

Regulation of anti-tumor immunity in PDAC stroma by IGF signaling

The dynamic stroma can also regulate anti-tumor immunity [45]. Wide range of studies have implied the involvement of CCL5/CCR5 signaling axis in anti-tumor immunity, invasion and metastasis [46]. Interestingly, IGF-1 maintains secretion of CCL5 from stromal cells, in particular mesenchymal stem cells that are in physical contact with PDAC cancer cells in vitro, resulting in the recruitment of tumor-targeting immune cells [47]. Importantly, active signalling through IGF-1R is needed for this cross-talk [46, 47]. Like pancreatic myofibroblasts, tumor associated macrophages (TAMs) are the other stromal source of IGF ligands [48]. Recently, it has been found that TAM infiltration in PDAC patients is correlated with increased IR/IGF-1R expression, and inhibition of IR/IGF-1R axis in preclinical diseases models improves chemotherapy responses [48].
Hyperinsulinemia promotes stromal activation and fibrosis in PDAC

Western-type high fat diet can result in hyperinsulinemia, and over time lead to hyperglycemia due to insulin resistance, and particularly to elevated IGF-1 levels in the circulation. This metabolic derangement was shown to activate PaSCs that express IR-A and IGF-1 receptors [49], and to boost stromal fibrosis and also specifically fibrosis within islets, which is typically encountered in T2DM [50, 51].

Impact on the exocrine-endocrine crosstalk in PDAC

Previous studies suggested that insulin/IGF signaling can affect both the exocrine and endocrine compartment of the pancreas. In the exocrine compartment, IGF-1 is mainly responsible for acinar cell regeneration and regulation of amylase synthesis [52]. Indeed, IGF-1 that is secreted from fibroblasts was shown to promote acinar cell recovery during acute pancreatitis [53]. Besides, IGF-1 can reduce the tissue damage due to caerulein-induced pancreatitis [54]. Moreover, after partial pancreatectomy in mice, acinar cell proliferation was linked to IGF-1 presence in the microenvironment and was hampered in aging mice due to the loss of responsiveness to IGF-1 [55, 56].

The impact of Insulin/IGF signalling on development and function of the endocrine pancreas has been extensively studied and summarized before [57–59]. In the endocrine compartment, IGFs, IGF-1R and IGFBPs were shown to control the function of β-cells. IGF-1 can stimulate β-cell proliferation and increase β-cell mass, increase basal insulin production regardless of mass proliferation [60–63]. Furthermore, low levels of circulating IGF-1 reduces β-cells function [64]. On the other hand, IGF-2 ligand overexpression has been found to damage the function of β-cells in vivo [65]. Interestingly, IGFBP-3 also affects β-cells. In vitro studies suggested that IGFBP-3 can trigger apoptosis in insulin-secreting cells [66]. Moreover, IGFBP-3 is able to regulate insulin secretion from β-cells in response to glucose, in vivo [67].

Substantial evidence suggests that both endocrine islets and exocrine pancreas tissue can modulate each other’s function. Earlier studies that had been conducted with mouse models of type I diabetes mellitus, disclosed that hormone secretion from islets modulate the structure and the functionality of exocrine cells in the pancreas [68–71]. Interestingly, in mouse models of type II diabetes mellitus and in diabetic patients, extracellular matrix in-between islets and acinar cells is frequently lost [72]. Tissue fibrosis and pericapillary fibrosis in the islets lead to loss of cell to cell communication between islets and acinar cells [72]. Thus, this phenomenon may not only alter the trophic effects of the endocrine cells on the exocrine cells, but also diminish the efficient use of digestive enzymes by gut and thereby cause maldigestion [72]. Besides, it is also imaginable that alterations in IGFBP levels in the PDAC stroma can be indirectly responsible for loss of islets and emergence of diabetes and maldigestion in PDAC. Of note, one should consider that endocrine β-cells that express oncogenic K-ras can also be one potential progenitor for PDAC under chronic tissue inflammation [73]. Overexpression of transcription factors that normally control endocrine differentiation during embryonic development (i.e.,
Neruogenin 3, Pax6, MafA, Pdx1) in ductal cells can lead to exocrine-endocrine differentiation [74–76]. Moreover, ductal cells are able to undergo ductal-endocrine differentiation in the presence of proinflammatory cytokines such as TNF-α, IL-1β and IFN-γ via STAT3 activation [77]. Interestingly, endocrine progenitors like Sox9 (+) /Pdx1 (+) /Ngn3(+) cells are found in the intercalated ducts of adult pancrea [78]. Moreover, patients with chronic pancreatitis were reported to have insulin-expressing ‘islet progenitors’ on their ducts [79]. Whether such cells are present in the PDAC stroma has yet to be investigated.

The function of these insulin-expressing cells on pancreatic ducts in the normal and diseased pancreas is also currently unknown. Moreover, the potential role of insulin-secreting endocrine cells in the progression of PDAC and the impact of PDAC tumor microenvironment on insulin-secreting endocrine cells is yet to be discovered. Such a “three-way”, insulin/IGF-driven interaction between exocrine/cancer cells, endocrine pancreas, and the stroma may be key to understanding the progression of PDAC and of PDAC-associated diabetes (Fig. 3).

The impact of insulin/IGF-1R signaling on chemotherapy and targeted therapies in PDAC: current and novel directions

PDAC is frequently resistant to the current chemotherapy regimens. Recently, FOLFIRINOX, a novel chemotherapy regimen containing four different chemotherapy drugs (folinic acid, fluorouracil, oxaliplatin and irinotecan) was reported to increase the overall survival of patients with unresectable metastatic PDAC to 11.1 months from 6.8 months, a success rate that is far from being satisfying [80]. This fact points out the urgent need of developing novel treatment strategies or novel targeted therapeutics.

There is accumulating evidence suggesting that IGF-1R pathway inhibitors may enable conceivable benefits in PDAC treatment. Aiming to overcome chemotherapy resistance and to develop better adjuvant therapies within the last decade, many different small molecule inhibitors/monoclonal antibodies against IGF-1R and neutralizing antibodies against IGF ligands have been developed and tested in pre-clinical studies. Even though promising results were obtained with the developed compounds during in vitro, during pre-clinical studies in vivo, and at Phase I/Phase II clinical trials, the overall outcome of advanced clinical trials is yet disappointing. Table 1 provides a comprehensive overview of clinical trials that target insulin/IGF signalling in pancreatic cancer (Table 1).

Insulin/IGF-1R signaling is one of the signaling pathways that govern the sensitization of cancer cells to gemcitabine [48, 81]. Secreted IGFs from activated myo-fibroblasts directly act on IGF-1R, which promotes resistance to gemcitabine in pre-clinical studies [48, 81]. However, combined administration of gemcitabine with ganitumab, a monoclonal antibody that inhibits IGF-1R activity, did not show any significant improvement in the survival of PDAC patients (Table 1) [82]. In another strategy, gemcitabine in combination with cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, also failed to show any improvement in survival during Phase II/Phase III trials [83]. Recently, MM-141, a tetravalent bispecific antibody that recognizes IGF-1R and EGFR family member ErbB3, provided promising results in pre-clinical studies [84]. Currently, MM-141 is being tested in Phase II clinical trials in combination with Nab-paclitaxel plus gemcitabine (Table 1, NCT02399137). As another approach, researchers have been testing the effect of another IGF-1R monoclonal antibody, MK-0646, in combination with gemcitabine and erlotinib, an RTK inhibitor that targets EGFR (Table 1, NCT00769483). Even though dual inhibition of IGF-1R/EGFR sounds promising, one should remember that IGF-1R and IR show high homology. Hence, even if IGF-1R receptors are inhibited together with other receptors that promote PDAC progression, IR receptors and hybrid IR/IGF-1R receptors that show strong resemblance to IGF-1R, can be still active and take over the function of the blocked IGF-1R receptor in the presence of insulin or IGFs. Blockade of insulin receptors may have wide-ranging systemic side effects, such as hyperglycemia. One way to overcome this problem is to use specific neutralizing antibodies against IGF-1/IGF-2. Indeed, in pre-clinical studies, cancer proliferation and tumor-promoting effects of mTOR signaling are reduced by BI836845, a neutralizing antibody against IGFs [85]. Phase I clinical trials of this agent in combination with other drugs in non-small-cell lung cancer and prostate cancer are ongoing (NCT02191891 and NCT02204072, respectively). However, studies that investigate the efficacy of this agent in PDAC currently do not exist.

Multiple trials testing therapy regimens that combine conventional cytotoxic drugs with molecules that target IGF-1R signaling have failed to show a major impact on the natural progression of PDAC. Although dual inhibition of IGF-1R signaling together with another RTK that is involved in PDAC progression is the current focus, it is crucial to choose the best partner to inhibit. Moreover, most of the compounds that target IGF-1R signaling either inhibit specifically IGF-1R activation or neutralize IGF-1 and IGF-2. Researchers have not known whether neutralizing antibodies are efficient and completely block the side effects of elevated levels of IGFs in the tissue. Besides, the source and the function of the increased amounts of IGFs in cancer stroma has only been recently identified. Pancreas is a complex tissue, and we should build on our knowledge on the impact of enhanced IGF-1R signaling on the “three-way”, insulin/IGF-driven interaction between cancer cells, endocrine pancreas, and the stroma.
| Author/Principal investigators | Malignancy | Treatment | NCT accession number | Enrollment number | Phase | Status | Study type | Primary outcome/objectives | Summary of results |
|-------------------------------|------------|-----------|----------------------|-------------------|-------|--------|------------|---------------------------|------------------|
| Kindler, H.L. et al. [86]     | Metastatic pancreatic cancer | Drug 1: Placebo+ Gemcitabine  
Drug 2: Ganitumab (a mAb antagonist of IGF-1R) + Gemcitabine | NCT00630552 | 42 | II | Completed | Randomized Open label Placebo controlled | To evaluate the efficacy and safety of Ganitumab/Gemcitabine treatment in patients with metastatic pancreatic cancer | A slight improvement in 6-month survival rate in patients who are treated with Ganitumab/Gemcitabine compared to the patients who have received Gemcitabine monotherapy has been observed |
| Fuchs, C.S. et al. [82]       | Metastatic pancreatic adenocarcinoma | Drug 1: Placebo+ Gemcitabine  
Drug 2: Ganitumab+ Gemcitabine | NCT01231347 | 825 | III | Terminated | Randomized Double blind Placebo controlled Multicenter | To evaluate the efficacy and safety of Ganitumab/Gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma | No improvement in the survival rate of patients that are treated with Ganitumab/Gemcitabine compared to the patients that received Gemcitabine monotherapy |
| Tabernero, J. et al. [87]     | Advanced, refractory solid tumours including pancreatic cancer | Drug 1: Ganitumab  
Drug 2: Conatumumab, (mAb that binds to DR5) | NCT00819169 | 89 | Ib-II | Terminated | Non-randomized Open label Parallel assignment | Phase Ib: To determine the dose of Ganitumab/Conatumumab treatment.  
Phase II: To evaluate the efficacy of the combined Ganitumab/Conatumumab treatment in patients with pancreatic, lung, colorectal, ovarian cancers and sarcoma | Ganitumab/Conatumumab treatment is safe to apply but has no effects on survival rate of patients in the tested population |
| Phillip P.A et al. [88]      | Stage IV pancreatic cancer | Drug 1: Cixutumumab (mAb antagonist of IGF-1R)  
Drug 2: Erlotinib (EGFR Inhibitor)  
Drug 3: Gemcitabine | NCT00617708 | 134 | Ib-II | Completed | Randomized Open label Parallel assignment | Phase Ib: To determine the dose of Cixutumumab to be used in combination with Erlotinib/Gemcitabine  
Phase II: To evaluate the efficacy of Cixutumumab/Erlotinib/Gemcitabine in patients with pancreatic cancer | No difference in progression free survival of patients who received Cixutumumab/Erlotinib/Gemcitabine treatment compared to the patients that are treated with Erlotinib/Gemcitabine |
| Javle, M. et al.              | Pancreatic adenocarcinoma | Drug 1: MK-0646 (Dalotuzumab- mAb, IGF-1R antagonist)  
Drug 2: Gemcitabine  
Drug 3: Erlotinib | NCT00769483 | 100 | I-II | On-going, not recruiting participants | Randomized Open label Parallel assignment | Phase I: To determine the 'maximum tolerated dose (MTD)' of MK-0646/Gemcitabine, MK-0646/Gemcitabine/Erlotinib and Gemcitabine/Erlotinib combined therapy  
Phase II: To evaluate the 'progression free survival' under the three different therapies with the MTD determined in Phase I | Results are expected by November 2018 |
| Braghinoli, M.I. et al. [89]  | Advanced metastatic pancreatic cancer | Drug 1: Paclitaxel  
Drug 2: Metformin | NCT01971034 | 41 | II | Completed | Open label Single group assignment | To evaluate efficacy of Metformin/Paclitaxel treatment compared to the standard Paclitaxel monotherapy | Combined therapy was poorly tolerated by patients and did not improve state of the disease in patients |
| Renouf, D.J. (British Columbia Cancer Agency) | Drug 1: Metformin | NCT02978547 | 20 | II | On-going, not open yet to recruit participants | Open label Single group assignment | To evaluate the effect of neoadjuvant metformin treatment on tumor cell growth | Results are expected by January 2019 |
Table 1  Summary of clinical trials that target insulin/IGF signalling in PDAC (Continued)

| Author/Principal Investigators | Malignancy | Treatment | NCT accession number | Enrollment number | Phase | Status | Study type | Primary outcome/objectives | Summary of results |
|-------------------------------|------------|-----------|----------------------|-------------------|-------|--------|------------|---------------------------|-------------------|
| Merrimack Pharmaceuticals      | Metastatic pancreatic adenocarcinoma | Drug 1: MM-141 Drug 2: Placebo Drug 3: Gemcitabine Drug 4: Nab-Paclitaxel | NCT02399137 | 260 | II | On-going, recruiting participants | Randomized Double blind Placebo control Parallel assignment | To evaluate the efficiency of MM-141/Nab-Paclitaxel/ Gemcitabine combined therapy compared to the Nab-Paclitaxel/ Gemcitabine therapy | Results are expected by November 2018 |
| Yeh, J. (John Hopkins University) | Solid tumors including pancreatic cancer | Drug 1: Metformin Behavioral 1: Coach-directed behavioral weight loss Behavioral 2: Self-control weight loss | NCT02431676 | 120 | II | On-going, recruiting participants | Randomized Single blind Parallel assignment | To evaluate the IGF-1 levels and IGF-1/IGFBP-3 ratio in the serum of participants within the next 6 and 12 months survival after surgery. | Results are expected by June 2018 |
| Suleiman, Y. et al. [90]       | Advanced or metastatic pancreatic cancer | Drug 1: SOM 230 LAR (somatostatin agonist and potent IGF-1R inhibitor) Drug 2: Gemcitabine | NCT01385956 | 20 | I | Completed | Open label Single group assignment | To evaluate the safety and tolerability of SOM 230 LAR/ Gemcitabine treatment | Treatment is well tolerated |
Based on the knowledge depicted above, we propose that 1) specific targeting of stroma-cell-derived IGFs, and 2) targeting the levels of stroma-derived IGFBPs can have more promising traits in the therapy of PDAC. Focusing more on this phenomenon can help researchers to identify novel therapy targets for dual inhibition IGF-1R signaling, and other signaling pathways, and thereby can create an opportunity for dual targeting of stroma and cancer cells.

**Conclusion**

Insulin/IGF-1R signaling axis is one of the multiple dysregulated pathways in PDAC, and its roles in the progression of PDAC seem to be multifold. Although there are enormous efforts to develop novel targeted therapies against this signaling axis, recent clinical trials have not been successful. Evidence from cancers other than PDAC suggest that usage of neutralizing agents against IGF-1/IGF-2 can be a promising approach. However, an under-investigated niche is the role of stromal insulin/IGF-1 signaling and the contribution of IGFBPs. Tailored, targeted therapies against *stromal* insulin/IGF-1 signaling can have beneficial effects both on cancer progression and the deregulated endocrine function. Thus, targeting the stromal activity of this pathway may be a novel, viable option in the future treatment of PDAC.

**Authors’ contributions**

ACM, HEB and IED drafted the first version of the manuscript, SW contributed the literature search and review. HF and GOC supervised the review process. All authors have critically reviewed and approved the manuscript.

**Competing interests**

All authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Surgery, Klinikum rechts der Isar, Technical University Munich, München, Germany. 2Department of Histology and Embryology, Gazi University Institute of Health Sciences, Ankara, Turkey.

**Received:** 22 April 2017 **Accepted:** 1 February 2018

**Published online:** 23 February 2018

**References**

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.

2. Gong J, Robbins LA, Lugea A, Waldron RT, Jeon CY, Pandol SJ. Diabetes, pancreatic cancer, and metformin failure. Front Physiol. 2014;5:426.

3. Vincent A, Herrman J, Schullick R, Huban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.

4. Onitilo AA, Engell JM, Gluch I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967–81.

5. Cotterill AM, Holly JM, Wass JA. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin Endocrinol. 1993;39(3):357–62.

6. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28.

7. Balyes EA, Nave BT, Soos MA, Orr SR, Hayward AC, Siddke K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997;327(Pt 1):1209–15.

8. Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, Lauro D, Sesti G. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Mol Cell Endocrinol. 1997;129(2):121–6.

9. Boucher J, Kleinittaders A, Kahn CR. Insulin receptor signalling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1).

10. Belfiore A, Frasca F, Pandini G, Silacca L, Viglenti R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586–623.

11. Rajapaksha H, Forbes BE. Ligand-binding affinity at the insulin receptor isoform-a and subsequent IR-A tyrosine Phosphorylation kinetics are important determinants of Mitogenic biological outcomes. Front Endocrinol (Lausanne). 2015;6:107.

12. Siddle K. Signalling by insulin and insulin receptors: supporting acts and new players. J Mol Endocrinol. 2011;47(1):1–10.

13. Bergmann U, Funatomi H, Yokoyama M, Beger HG. K. M. insulin-like growth factor I Overexpression in human pancreatic cancer: evidence for Autocrine and Paracrine roles. Cancer Res. 1995;55:5.

14. Ohnura E, Okada M, Onoda N, Kariyi Y, Murakami H, Tsuchiia T, Shizume K. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. 1990;50(1):103–7.

15. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freybin D, Bao Y, Cio, Solomides C, Peiper SC, Witzliewicz AK. Epidermal growth factor receptor and insulin-like growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118(14):3484–93.

16. Ishivata T, Bergmann U, Kommmann M, Lopez M, Beger HG, Korc M. Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas. 1997;15(4):367–73.

17. Brahmkhpati VP, Prasanna C, Areyha HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015;2015:538019.

18. Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiba K, Souza RF, Meltzer SJ, et al. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res. 1997;57(10):1851–4.

19. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–54.

20. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329–41.

21. Kama E, Surazynski A, Olewski K, Laszkiewicz J, Puchalski Z, Nawrat P, Palka J. Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. J Int Exp Pathol. 2002;83(5):239–45.

22. Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, Kawamura T, Inaba Y, Kurosawa M, Motohashi Y, et al. Serum insulin-like growth factor I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer. 2004;110(4):584–9.

23. Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjonneland A, Roswall N, Gronbaek H, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Br J Cancer. 2012;106(5):1004–10.
associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreatic cancer with reduced survival. Cancer Cell. 2014;25(6):735–47.

29. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111(5):817–22.

30. Scales SJ, de Sauvage FJ. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30(6):303–12.

31. Tape CJ, Ling S, Dimitriadis M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, et al. Oncogenic KRAS regulates tumor cell signaling via Stromal reciprocal signaling. Cell. 2016;165(4):910–20.

32. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res. 1995;6(2–4):273–84.

33. Ceyhan GO, Schafer KH, Kopersch AG, Rauh U, Demir IE, Kadihasanoglu M, Bohm C, Muller MW, Buchler MW, Giese NA, et al. Nerve growth factor and artemin are paracrine mediators of pancreatic neurogenesis in pancreatic adenocarcinoma. Ann Surg. 2010;251(5):923–31.

34. Rajah R, Bhalia A, Nunn SE, Peehl DM, Cohen P. 75 nerve growth factor is an insulin-like growth factor-binding protein protease. Endocrinology. 1996;137(7):2676–82.

35. Braule T, Claussen M, Safi P, Wendland M, Neffr K, Schmidt B, Zapf J, von Figure K, Peters C. Proteolysis of IGFBPs by cathepsin D in vitro and in cathespin D-deficient mice. Prog Growth Factor Res. 1995;6(2–4):265–71.

36. Park HD, Kang ES, Kim JW, Lee KT, Lee KH, Park YS, Park JO, Lee J, Heo JS, Choi SH, et al. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics. 2011;12(23–24):3590–7.

37. Jakubowska K, Przybylska K, Januszewska J, Sidorkiewicz I, Kemona A, Jakubowska A. Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I. Exp Cell Res. 2015;339(2):190–300.

38. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res. 1995;6(2–4):273–84.

39. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A. Matrix metalloproteinase-7 in the extracellular matrix in the development of caerulein-induced pancreatitis. J Physiol Pharmacol. 2015;66(5):774–83.

40. Prudova A, on dem Keller U, Butler GS, Overall CM. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradation by ITRAQ-TAILS quantitative proteomics. Mol Cell Proteomics. 2010;9(5):894–911.

41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

42. Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediat Inflamm. 2014;2014:929376.

43. Makrinoshtima H, Dezawa M. Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. FEBS Lett. 2009;583(22):2697–703.

44. Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quanta V, Weyer-Czerny I, Lloyd RE, Perez-Manresa PA, Coupland SE, et al. Chemoresistance in pancreatic cancer is driven by Stroma-derived insulin-like growth factors. Cancer Res. 2016;76(23):6851–63.
72. Hayden MR, Patel K, Habibi J, Gupta D, Tekwani SS, Whaley-Connell A, Sowers JR. Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr. 2008;4(2):234–43.

73. Gidekel Friedlander SY, Chu GC, Snyder EL, Gimius N, Dilibello G, Crowley D, Vasile E, DePinto RA, Jacks T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 2009;16(3):379–89.

74. Azzarelli R, Hurley C, Sznurkowska MK, Rulands S, Hardwick L, Gumper J, Ali F, McCracken L, Hindley C, McDuff F, et al. Multi-site Neurogenin3 Phosphorylation controls pancreatic endocrine differentiation. Dev Cell. 2017;41(3):274–86. e279.

75. Lee J, Sugiyama T, Liu Y, Wang J, Gu X, Lei J, Markmann JF, Miyazaki S, Miyazaki I, Sztol GJ, et al. Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells. Cell. 2013;200940.

76. Smith SB, Watada H, German MS. Neurogenin3 activates the islet differentiation program while repressing its own expression. Mol Endocrinol. 2004;18(1):142–9.

77. Valdez IA, Dirice E, Gupta MK, Shirakawa J, Teo AKK, Kulkarni RN. Proinflammatory cytokines induce endocrine differentiation in pancreatic Ductal cells via STAT3-dependent NGS activation. Cell Rep. 2016;15(3):460–70.

78. Carpino G, Renai A, Cardinale V, Franchitto A, Doni P, Overi D, Rossi M, Berloco PB, Alvaro D, Reid LM, et al. Progenitor cell niches in the human pancreatic duct system and associated pancreatic ductal glands: an anatomical and immunophenotyping study. J Anat. 2016;228(3):474–86.

79. Phillips JM, O’Reilly L, Bland C, Foulis AK, Cooke A. Patients with chronic pancreatitis have islet progenitor cells in their ducts, but reversal of overt diabetes in NO mice by anti-CD3 shows no evidence for islet regeneration. Diabetes. 2007;56(S):634–40.

80. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gougou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

81. Tian X, Hao K, Qin C, Xie K, Xie X, Yang Y. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Dig Dis Sci. 2013;58(9):2705–12.

82. Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Fuchs JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Atkins AJ, Mirtsching BH, Rivkin SE, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605–10.

83. Phillips PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins AJ, Mirtsching BG, Rivkin SE, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605–10.

84. Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014;13(2):410–25.

85. Friedbichler K, Hofmann MH, Kroezer M, Ostermann E, Lamche HR, Koessl C, Borges E, Pollak MN, Adolf G, Adam PJ. Pharmacodynamic and Antineoplastic activity of BI 836845, a fully human IGF Ligand-neutralizing antibody, and mechanistic rationale for combination with Rapamycin. Mol Cancer Ther. 2014;13(2):399–409.

86. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Roche-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or cetuximab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012;23(11):2894–402.

87. Taberner J, Chavla SP, Kindler H, Reckamp K, Choeke EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, et al. Anticancer activity of the type I insulin-like growth factor receptor agonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Mol Cancer Ther. 2015;10(6):165–76.

88. Philip PA, Goldeman B, Ramanananth RK, Lenz HJ, Lowy AM, Whitehead RP, Wakahsuki T, Iqbal S, Gaur R, Benedetti JK, et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of ganitumab, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014;120(19):2980–5.

89. Biaghirollo M, de Celler Ferran AC, Pifferi TE, Alex AK, Nebuloni D, Carneiro AS, Caparelli F, Senina L, Lobo J, Hoff PM, et al. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Eancermed. 2015;9563.

90. Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WI, Springett GM, Kim R. Phase I study of combination of paclitaxel LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015;76(3):481–7.